Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Feb 1.

Published in final edited form as: Neurosurgery. 2012 Feb;70(2):497–510. doi: 10.1227/NEU.0b013e31823209cf

JS-K reduces proliferation of U87 and primary glioblastoma cells in a dose-dependent fashion in vitro. A. Cell proliferation was assessed by 5’-bromodeoxyuridine incorporation 48 h after treatment of glioma cells with JS-K (1-10 μM) for 24 h. Percentage of proliferating cells out of 100% vital cells was assessed by fluorescence microscopy. Data are expressed as means ± SEM from three independent experiments and analyzed by t-test. Asterisks (*, p< .05; **, p< .01; ***, p< .001) indicate a significant difference between JS-K and the controls. B. Representative images of U87 cells treated with increasing concentrations of JS-K (1-10 μM) for 24 h. Photomicrographs taken on a Zeiss Axio Observer Microscope, scale bar 25 μm.

JS-K reduces proliferation of U87 and primary glioblastoma cells in a dose-dependent fashion in vitro. A. Cell proliferation was assessed by 5’-bromodeoxyuridine incorporation 48 h after treatment of glioma cells with JS-K (1-10 μM) for 24 h. Percentage of proliferating cells out of 100% vital cells was assessed by fluorescence microscopy. Data are expressed as means ± SEM from three independent experiments and analyzed by t-test. Asterisks (*, p< .05; **, p< .01; ***, p< .001) indicate a significant difference between JS-K and the controls. B. Representative images of U87 cells treated with increasing concentrations of JS-K (1-10 μM) for 24 h. Photomicrographs taken on a Zeiss Axio Observer Microscope, scale bar 25 μm.